Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Abstract Background In Japan, the clinical efficacy of erlotinib monotherapy in epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …

Aims: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …

Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Purpose Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
were firmly established as front-line treatment for non–small cell lung cancer (NSCLC) that …